A5035020537- Acute Myeloid Leukemia Research
- Sarcoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Cancer Genomics and Diagnostics
- Hematopoietic Stem Cell Transplantation
- Natural product bioactivities and synthesis
- Computational Drug Discovery Methods
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Electrical and Thermal Properties of Materials
- Multiple Myeloma Research and Treatments
- Orthopaedic implants and arthroplasty
- Childhood Cancer Survivors' Quality of Life
- Bone Metabolism and Diseases
- Bone health and treatments
- Advancements in Battery Materials
- Bone health and osteoporosis research
- Aluminum Alloys Composites Properties
- Histone Deacetylase Inhibitors Research
- Magnesium Alloys: Properties and Applications
- Hematological disorders and diagnostics
- Pharmacological Effects of Natural Compounds
Institute of Hematology & Blood Diseases Hospital
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
Zhangjiagang First People's Hospital
2022
Soochow University
2022
Affiliated Zhongshan Hospital of Dalian University
2022
Abstract Purpose: Patient-tailored minimal residual disease (MRD) monitoring based on circulating tumor DNA (ctDNA) sequencing of leukemia-specific mutations enables early detection relapse for pre-emptive treatment, but its utilization in pediatric acute myelogenous leukemia (AML) is scarce. Thus, we aim to examine the role ctDNA as a prognostic biomarker response treatment AML. Experimental Design: A prospective longitudinal study with 50 children AML was launched, and sequential bone...
Abstract Jinlida granule (JLD) is a Traditional Chinese Medicine (TCM) formula used for the treatment of type 2 diabetes mellitus (T2DM). However, mechanism JLD T2DM not fully revealed. In this study, we explored against by an integrative pharmacology strategy. Active components and corresponding targets were retrieved from System Pharmacology (TCMSP), SwissADME Bioinformatics Analysis Tool Molecular Mechanisms Database (BATMAN-TCM) database. T2DM-related obtained Drugbank Genecards...
Abstract The two most critical factors in promoting the clinical translation of magnesium (Mg) are reducing its degradation rate and improving osteogenesis. In this study, a Ca-deficient hydroxyapatite (CDHA)/MgF2 bilayer coating was prepared on high-purity (HP Mg) rods by fluorination hydrothermal treatment. Scanning electron microscope showed that thickness 3.78 μm surface morphology nanoscale. an vivo experiment femoral condyle defects rabbits, serum ion levels rabbits were always normal...
Osteoporosis (OP) is a common metabolic bone disease mainly involving remodeling and blood vessels. The current study aimed to explore the role of zinc finger E-box binding homeobox 1 (ZEB1) in OP.First, gene expression microarrays for OP were downloaded from Gene Expression Omnibus database analyzed screen potential targets. Subsequently, rat model was constructed using ovariectomy (OVX), osteoblastic osteoclastic differentiation alterations osteoporotic symptoms observed upon...
<div>AbstractPurpose:<p>Patient-tailored minimal residual disease (MRD) monitoring based on circulating tumor DNA (ctDNA) sequencing of leukemia-specific mutations enables early detection relapse for pre-emptive treatment, but its utilization in pediatric acute myelogenous leukemia (AML) is scarce. Thus, we aim to examine the role ctDNA as a prognostic biomarker response treatment AML.</p>Experimental Design:<p>A prospective longitudinal study with 50 children AML was...
<p>Figure S3. Kaplan-Meier plot showed the PFS of patients diagnosed as CBF and non-CBF AML underwent dynamic monitoring mutations by ctDNA from admission to last cycle chemotherapy. PFS, progression-free survival. CBF, core binding factor</p>
<p>Figure S2. Comparison of CIR stratified by the different timepoint post treatment residual status either plasma ctDNA (A-C) or mutation in BM (D-F). according to (A) (D) at C2D1 treatment; (B) (E) C3D1 (C) (F) C4D1 treatment. A higher was associated with patients DNA positive results any point (all p<0.001). BM, bone marrow; CIR, cumulative incidence relapse; C2D1, Cycle 2 day 1; C3D1, 3 C4D1, 4 1</p>
<p>Figure S1. Flowchart of patient selection and enrollment. In total, 50 patients 195 paired samples (ctDNA BM DNA) from this population can be analyzed. the last row, plasma included at separate timepoint were depicted. BM, bone marrow; C2D1, Cycle 2 day 1; C3D1, 3 C4D1, 4 1</p>
<p>Figure S4. The correlation of the VAFs in patient-specific tumor mutation site detected plasma ctDNA and matched MFC based MRD. Scatter plot 195 individual mutations by both methods (r=0.586, p<0.001).</p>
<div>AbstractPurpose:<p>Patient-tailored minimal residual disease (MRD) monitoring based on circulating tumor DNA (ctDNA) sequencing of leukemia-specific mutations enables early detection relapse for pre-emptive treatment, but its utilization in pediatric acute myelogenous leukemia (AML) is scarce. Thus, we aim to examine the role ctDNA as a prognostic biomarker response treatment AML.</p>Experimental Design:<p>A prospective longitudinal study with 50 children AML was...
<p>Figure S3. Kaplan-Meier plot showed the PFS of patients diagnosed as CBF and non-CBF AML underwent dynamic monitoring mutations by ctDNA from admission to last cycle chemotherapy. PFS, progression-free survival. CBF, core binding factor</p>
<p>Figure S5. Comparison of PFS stratified by the different timepoint post-treatment residual status either plasma ctDNA or MFC at (A) C2D1, (B) C3D1 and (C) C4D1 post-treatment. neg-MFC neg was defined as VAF mutation being negative for MRD each timepoint. pos-MFC >0.01% pos immunophenotype ≥10−4 myeloblasts MFC, multiparameter flow cytometry; Cycle 2 day 1; C3D1, 3 C4D1, 4 1</p>
<p>Figure S2. Comparison of CIR stratified by the different timepoint post treatment residual status either plasma ctDNA (A-C) or mutation in BM (D-F). according to (A) (D) at C2D1 treatment; (B) (E) C3D1 (C) (F) C4D1 treatment. A higher was associated with patients DNA positive results any point (all p<0.001). BM, bone marrow; CIR, cumulative incidence relapse; C2D1, Cycle 2 day 1; C3D1, 3 C4D1, 4 1</p>
<p>Figure S5. Comparison of PFS stratified by the different timepoint post-treatment residual status either plasma ctDNA or MFC at (A) C2D1, (B) C3D1 and (C) C4D1 post-treatment. neg-MFC neg was defined as VAF mutation being negative for MRD each timepoint. pos-MFC >0.01% pos immunophenotype ≥10−4 myeloblasts MFC, multiparameter flow cytometry; Cycle 2 day 1; C3D1, 3 C4D1, 4 1</p>
<p>Figure S4. The correlation of the VAFs in patient-specific tumor mutation site detected plasma ctDNA and matched MFC based MRD. Scatter plot 195 individual mutations by both methods (r=0.586, p<0.001).</p>
<p>Figure S1. Flowchart of patient selection and enrollment. In total, 50 patients 195 paired samples (ctDNA BM DNA) from this population can be analyzed. the last row, plasma included at separate timepoint were depicted. BM, bone marrow; C2D1, Cycle 2 day 1; C3D1, 3 C4D1, 4 1</p>